EDIT
Price
$2.67
Change
-$0.26 (-8.87%)
Updated
Oct 30 closing price
Capitalization
410.06M
9 days until earnings call
Intraday BUY SELL Signals
PCVX
Price
$62.03
Change
-$0.58 (-0.93%)
Updated
Oct 30 closing price
Capitalization
9.23B
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs PCVX

EDIT vs PCVX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. PCVX commentary
Nov 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and PCVX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Oct 30, 2026

EDIT's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 68 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

Following a +22.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.895) is normal, around the industry mean (3.154). P/E Ratio (-4.045) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.237).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PCVX with price predictions
Oct 30, 2026

PCVX in upward trend: price rose above 50-day moving average on October 29, 2026

PCVX moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 65 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.

Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 223 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 24 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.

The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In 59 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for PCVX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 33 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.347) is normal, around the industry mean (3.154). P/E Ratio (-8.130) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
EDIT vs PCVX: Fundamental Ratings
EDIT
PCVX
OUTLOOK RATING
1..100
8480
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
4440
P/E GROWTH RATING
1..100
3659
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCVX's Valuation (20) in the null industry is somewhat better than the same rating for EDIT (54) in the Biotechnology industry. This means that PCVX’s stock grew somewhat faster than EDIT’s over the last 12 months.

PCVX's Profit vs Risk Rating (72) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that PCVX’s stock grew similarly to EDIT’s over the last 12 months.

PCVX's SMR Rating (96) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that PCVX’s stock grew similarly to EDIT’s over the last 12 months.

PCVX's Price Growth Rating (40) in the null industry is in the same range as EDIT (44) in the Biotechnology industry. This means that PCVX’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's P/E Growth Rating (36) in the Biotechnology industry is in the same range as PCVX (59) in the null industry. This means that EDIT’s stock grew similarly to PCVX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITPCVX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
69%
COMPARISON
Comparison
Nov 01, 2026
Stock price -- (EDIT: $2.67 vs. PCVX: $62.03)
Brand notoriety: EDIT and PCVX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 112% vs. PCVX: 73%
Market capitalization -- EDIT: $410.06M vs. PCVX: $9.23B
EDIT [@Biotechnology] is valued at $410.06M. PCVX’s [@Biotechnology] market capitalization is $9.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $141.65B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while PCVX’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • PCVX’s FA Score: 1 green, 4 red.
According to our system of comparison, both EDIT and PCVX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while PCVX’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 5 bearish.
  • PCVX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both EDIT and PCVX are a bad buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а +11.25% price change this week, while PCVX (@Biotechnology) price change was +2.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

PCVX is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
PCVX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

PCVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with BCYC. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then BCYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCVX
1D Price
Change %
PCVX100%
-0.93%
BCYC - PCVX
57%
Loosely correlated
-4.19%
VIR - PCVX
46%
Loosely correlated
-3.83%
NVAX - PCVX
45%
Loosely correlated
-3.72%
PTGX - PCVX
44%
Loosely correlated
+0.35%
EDIT - PCVX
44%
Loosely correlated
-8.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
GLM.X0.1116420.009387
+9.18%
Golem cryptocurrency
LINK.X11.4371400.843191
+7.96%
Chainlink cryptocurrency
TKO.X0.0480400.002498
+5.49%
Toko Token cryptocurrency
BNT.X0.2879790.006297
+2.24%
Bancor cryptocurrency
FIO.X0.000335N/A
-0.09%
FIO Protocol cryptocurrency